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Abstract 
Background Many dementia and cardiovascular disease (CVD) cases in older adults are 
attributable to modifiable vascular and lifestyle-related risk factors, providing opportunities 
for prevention. In the Healthy Aging Through Internet Counselling in the Elderly (HATICE) 
randomized controlled trial, an internet-based multidomain intervention is being tested to 
improve the cardiovascular risk (CVR) profile of older adults. 
Objectives To design a multidomain intervention to improve CVR, based on the guidelines 
for CVR management, and administered through a coach-supported, interactive, platform to 
over 2500 community-dwellers aged 65+ in three European countries. 
Methods A comparative analysis of national and European guidelines for primary and 
secondary CVD prevention was performed. Results were used to define the content of the 
intervention. 
Results The intervention design focused on promoting awareness and self-management of 
hypertension, dyslipidemia, diabetes mellitus and overweight, and supporting smoking 
cessation, physical activity, and healthy diet. Overall, available guidelines lacked specific 
recommendations for CVR management in older adults. The comparative analysis of the 
guidelines showed general consistency for lifestyle-related recommendations. Key 
differences, identified mostly in methods used to assess the overall CVR, did not hamper the 
intervention design. Minor country-specific adaptations were implemented to maximize the 
intervention feasibility in each country. 
Conclusions Despite differences in CVR management within the countries considered, it was 
possible to design and implement the HATICE multidomain intervention. The study can help 
define preventative strategies for dementia and CVD that are applicable internationally.  
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Introduction 
Worldwide ageing of populations is strongly associated with dementia [1], as well as linked 
to increased occurrence of cardiovascular disease (CVD) [2], with both disorders causing 
major health, economic and social burdens [3,4]. The management of CVD is still suboptimal 
in many countries, especially among older adults [2], and no cure is available for Alzheimer’s 
disease (AD), the main cause of dementia. Therefore, prevention could be crucial both in 
reducing the occurrence of CVD and halting the rapid increase in the prevalence of dementia, 
as some projection models suggested [5,6]. Most CVDs are indeed attributable to modifiable 
risk factors – hypertension, hypercholesterolemia, diabetes mellitus (DM), obesity, smoking, 
physical inactivity, unhealthy diet, - which have also been linked also to dementia and AD [1-
4,7], providing opportunities for prevention. 
Prevention of dementia and CVDs in older adults is complex, as it requires a combination of 
primary and secondary prevention, and challenging, given the lack of evidence for this 
specific age group and individuals with existing comorbidity. Some cardiovascular risk 
factors (CVRFs, e.g., hypertension, hypercholesterolemia) are now labelled as actual 
diseases, even when they bear no symptoms [8], making the traditional distinction between 
primary and secondary prevention increasingly unclear and ‘‘more artificial than real’’ [9], 
from a public health perspective. Very limited data is available from clinical trials [10], thus 
robust scientific evidence to guide the treatment of CVRFs in older adults is lacking, making 
CVD prevention in this age group uncertain. Even less evidence is available within the field 
of dementia prevention. 
Due to the multi-factorial etiology of dementia, AD, and CVD, multidomain interventions 
simultaneously targeting several CVRFs seem most likely to be beneficial. However, 
evidence of the optimal target population and the most effective intervention is lacking [11], 
for strategies to manage CVRFs in this highly heterogeneous age group, in particular [12,13]. 
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Nevertheless, successful prevention trials for DM have highlighted the potential benefits of 
multidomain approaches [14,15]. The prevention of dementia/AD is a relatively new research 
area, but national guidelines for the management of CVRFs allow the development of 
preventative strategies. Recently, three, large randomized controlled trials (RCTs) [16-18] on 
prevention of dementia have tested pioneering multidomain interventions in older adults and 
addressed key methodological issues for the successful delivery of such strategies.  
The experience from these RCTs revealed the need for a wider, international approach, 
leading to the European Dementia Prevention Initiative (EDPI, www.edpi.org) and to the 
Healthy Aging Through Internet Counselling in the Elderly RCT (HATICE, trial registration 
number ISRCTN48151589) [19]. Within the HATICE project, an international, multidomain 
intervention RCT promoting vascular health through the internet is ongoing in Finland, 
France and the Netherlands. The aim of HATICE is to optimize the self-management of 
CVRFs, improve the cardiovascular risk (CVR) profile, and reduce the risk of CVD, 
cognitive decline and dementia. For the RCT, a generic evidence-based prevention strategy 
was developed based on the comparative analysis of national and European guidelines for the 
management of CVRFs. Here we describe the groundwork carried out to compare and 
integrate national guidelines of the three countries, and to design the HATICE intervention.   
 
Methods 
Comparison and synthesis of the European, Dutch, Finnish, and French Guidelines for 
CVRF management 
To support the European-wide setting and the evidence-based nature of the HATICE study, a 
comparative analysis of the guidelines for primary and secondary prevention of CVD was 
carried out. The latest guidelines for the management of CVRFs issued in the three 
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participating countries at the time of the completion of the HATICE design (June 2014), as 
well as the guidelines by the European Society of Cardiology (ESC), were collected and 
examined [20-27]. The risk factors considered were: hypertension, dyslipidemia, DM, 
overweight, smoking, physical inactivity, and unhealthy diet. Although the French guidelines 
for the managements of dyslipidemia have been withdrawn since their publication in 2005, 
they have not been replaced with newer documents. Therefore, those used in this study 
remain the most up to date available recommendations. Since the management of CVRFs 
depends on the individual overall risk to develop CVD, the methods to quantify the CVR 
were also compared. Documents and recommendations addressing older adults were sought 
for and used, when available. A thorough English summary was prepared for each document 
that required translation. 
Several parameters were extrapolated from each document: methods of assessment and 
normal range values of each risk factor; cut-off values to initiate lifestyle intervention and/or 
pharmacological treatment; content of the interventions; and specific recommendations for 
older adults. Main similarities and differences were identified across the countries, and data 
consistency examined to highlight potential difficulties in applying the intervention Europe-
wide. The ESC guidelines [27] were used as an overall reference, when country-specific 
differences were not compatible with a uniform approach, or national guidelines lacked of 
specific recommendations.  
Design of the intervention  
HATICE is an international, multi-center, randomized, open-label, blinded end-point trial 
with an 18-month intervention and follow-up period [19]. 2725 community dwellers aged 
65+ with at least two CVRFs, and/or personal history of DM or CVD consented to participate 
in the trial [19], resulting in a study population with indications for either primary or 
secondary CVD prevention. Key aspects of the trial design are summarized in Table 1. The 
8 
 
intervention is delivered through an interactive internet platform specifically designed for 
older adults; participants in the control arm access a simplified version of the platform, with 
only basic information and no interactive features [28]. Participants in the intervention arm 
have access to remote support of a lifestyle coach. The coach provides information, advice, 
and motivational support throughout the trial. 
The intervention was designed to promote self-management of seven CVRFs: hypertension, 
dyslipidemia, DM, overweight, smoking, physical inactivity and unhealthy diet.  
The results of the comparative analysis of the guidelines were used to define: the cut-off 
value for intervention, the content of the intervention platform, and recommendations 
provided by the coach. For all of the risk factors, cut-off values for lifestyle intervention were 
set to identify participants who were advised to act on a specific CVRF. Cut-off values for 
medical treatment were also set when applicable. However, as the HATICE intervention was 
not designed to have a pharmacological component, they were used to identify participants 
who were advised to seek medical assistance. When differences in cut-off values were 
identified among national guidelines, the value that maximized the number of participants 
eligible for intervention was chosen. The recommendations provided to the participants in the 
intervention arm were, when possible, specific for the age group (65+) and for the relevant 
level (primary or secondary) of prevention, and written to provide evidence-based, simple, 
reliable, and pragmatic advice that each individual could easily incorporate in his/her own 
unique lifestyle. The “Bandura’s theory for self-management and behavioral change” [29] 
was applied to define the conceptual structure of the intervention and the “Stages of 
Changes” [30,31] model provided the basis for the motivational support delivered by the 
coaches. 
 
Country-specific adjustments 
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The HATICE intervention was designed to not interfere with the healthcare services existing 
in each participating country, but rather complement them and facilitate CVRFs management 
in older adults. Therefore, it was crucial that the recommendations provided were always in 
keeping with national guidelines for CVRFs management and lifestyle habits. To ensure this, 
once the generic version of the intervention was finalized, minor country-specific 
adjustments were applied to both sections of the platform content and the coach protocol.  
 
Results 
Guidelines’ comparative analysis: similarities 
Overall, the Dutch, Finnish, and French guidelines for the management of CVRFs were 
uniform and in keeping with the European ones. Similarities existed especially in lifestyle-
related recommendations, and in the cut-off values that prompted interventions for specific 
risk factors.  
The recommendations for physical activity (derived from the WHO‘s guidelines) [32], 
smoking and diet, were strongly uniform across the national and European guidelines and 
only minor differences were identified (Table 2).  
Regarding risk factors assessed through biological or anthropometric measurements 
(hypertension, dyslipidemia, DM, overweight), eligibility for intervention depended on the 
overall CVR, which was assessed differently in the three countries. Nevertheless, it was 
possible to identify communal reference values for lifestyle interventions and/or 
pharmacological treatment (Table 3). In the French guidelines, initiation of pharmacological 
treatments was not based on specific cut-off values, but recommended when the therapeutic 
targets were not achieved following three months of lifestyle interventions. 
For hypertension, indications for a lifestyle intervention were well aligned for France 
(systolic blood pressure (SPB) ≥140mmHg and diastolic blood pressure (DPB) ≥90mmHg) 
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and Finland (SPB ≥130mmHg and DPB ≥85mmHg, consistent with the European 
recommendations). The Dutch Guidelines recommended lifestyle changes for blood pressure 
(BP) management depending on the 10-year CVR and presence of other CVRFs. The cut-offs 
for pharmacological treatment of people without history of CVD nor relevant comorbidities 
were set at SBP≥160mmHg and DBP≥100 by the Finnish and European Guidelines, and 
SBP≥180mmHg or SBP≥140mmHg and increased risk of CVD in the Dutch documents 
(Table 3). Since this analysis was carried out, new recommendations for the management of 
hypertension were published in Finland [33].  
The low-density lipoprotein (LDL)-cholesterol cut-off values for the treatment of 
dyslipidemia were more complex to define and to compare because different parameters were 
considered in each country (Table 3). In Finland, all the cut-off values were based on a 
combination of CVR and LDL level. In the other two countries, initiation of a 
pharmacological treatment depended on the LDL value alone, whereas lifestyle intervention 
was recommended based on LDL value (France) or presence of any other risk factors (the 
Netherlands).  
To assess blood glucose and DM, the three countries recommended different diagnostic tests, 
but for common tests, cut-off values for interventions were generally consistent (Table 3), 
with only minor differences. The French cut-off depended on a sequential approach similar to 
that for hypertension. The HbA1C cut-off values used for medical treatment prompted 
lifestyle interventions in all the three countries, confirming that pharmacological management 
of DM goes hand in hand with lifestyle interventions. The Finnish guidelines deviated from 
this pattern by recommending lifestyle changes in the pre-diabetes group with Fasting Plasma 
Glucose Test (FPGT) >6mmol/L or Oral Glucose Tolerance Test (OGTT) >7.8mmol/L. 
For overweight and obesity cut-off values were uniform throughout all guidelines: lifestyle 
intervention was consistently recommended for body mass index (BMI) ≥25. 
Recommendations for medical treatment were less uniform (Table 3). 
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Comparative analysis of guidelines: differences  
Main differences in guidelines were identified in only one key area: the assessment of the 
individual CVR. The CVR was classified as “low”, “moderate” or “high”, and affected cut-
off values for intervention on specific risk factors, and overall patient management. In the 
French guidelines, the CVR was defined by the sum of CVRFs, whereas in the other two 
countries it was calculated as the risk of developing CVD within 5 or 10 years. The Dutch 
CVR estimates derived from the ESC SCORE [27] and two Dutch cohorts [34,35] for the 
assessment of the 10-year risk of fatal CVD, and included information on sex, age, smoking 
status, cholesterol values, and SBP. In Finland, the FINRISK calculator [36], a 10-year risk 
score for fatal and non-fatal myocardial infarction and stroke, which included also 
information on  DM and family history of CVD, or the European SCORE [27] were 
recommended. All the listed risk assessment tools were developed for populations at different 
ages, and differences were identified in their upper age limit:  65 years for the European 
score, 70 for the Dutch, and 74 for FINRISK. The French guidelines attribute to each CVRF 
equal weight, whereas in other countries different CVRFs are given varying weights, making 
direct comparison impossible. 
Differences were also identified in the recommendations for pharmacological treatment for 
some of the CVRFs. Approaches to intervention for hypertension and dyslipidemia included 
detailed indications based on age, comorbidities, and overall CVR in all the countries, but 
recommendations about drugs of choice, and how to proceed from mono- to combination-
therapies varied greatly. Medical treatment targeting obesity was envisaged only in France 
and Finland. Finally, some differences existed in the protocols for the assessment of the 
CVRFs, in particular, in the number of blood pressure readings for hypertension and the type 
of tests used for DM.   
Recommendation for old and oldest-old individuals 
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As HATICE targets individuals aged 65+, the assessment of specific guidelines for old and 
oldest-old (age 85+) adults was deemed germane for the design of the intervention, and a key 
aspect of the comparative analysis. Overall, the guidelines examined lacked specific 
information on the management of CVRFs in older adults. This applied for both the 
calculation of the CVR, 74 years being the highest age limit (FINRISK score), and 
recommendations for the management of individual CVRFs, which were not consistently 
available in any country. For hypertension, the ESC issued specific guidelines for individuals 
aged 80+, which set cut-off values for both lifestyle and pharmacological interventions to 
SBP>160mmHg and DBP>100 mmHg [37]. The Dutch guidelines also provided advice for 
older adults and hypertension: pharmacological therapy was recommended for SPB>140 
mmHg if an initial lifestyle intervention did not result in an improvement, and SPB>160 
mmHg did not prompt immediately a pharmacological treatment for individual aged 80+, but 
lifestyle management was recommended first. The French guidelines had more lenient 
criteria for the pharmacological treatment of dyslipidemia in people aged 80+: initiation was 
not recommended, and continuation was advised only for patients with additional risk factors, 
lack of non-cardiovascular pathology and good treatment tolerance. Only the Finnish 
guidelines had age-specific recommendations for management of overweight/obesity in old 
individuals, for whom 25≤ BMI <30 was considered as a BMI in the normal range, and did 
not prompt a lifestyle intervention. In all three countries, the dietary guidelines had specific 
sections dedicated to older adults, and focused on ensuring sufficient nutrition among frail 
older adults with comorbidities. Among healthy older adults, the dietary recommendations 
for CVD prevention were similar to those of younger adults.  
For physical activity, all guidelines adjusted the recommendations depending on the general 
health status, prevention level (primary or secondary), and presence of comorbidities, rather 
than age. Regular mobility and balance training was additionally recommended in Finland 
and France. 
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In conclusion, a consistent approach aimed towards elderly individuals could not be 
identified across the guidelines analyzed. This is in keeping with recent evidence [10], and 
constantly affects CVRFs management in older adults.  
Design of the generic HATICE intervention  
Self-determination, management of realistic expectations, assessment of barriers, and goal 
setting are the key underlying principles included in the HATICE intervention, to promote 
and maintain behavioral change. They were applied based on the “Bandura’s theory for self-
management and behavioral change” [29], through a blended approach that combined the 
platform functionalities with the remote support of the coach.  
A generic algorithm structured in five main phases was designed to define the multidomain 
intervention for all the CVRFs (Figure 1): 
 1. Definition of eligibility; the participants who could benefit from a lifestyle intervention 
and/or medical treatment are identified based on cut-off values.  
2. Initiation of the intervention; the coach presents to the participants the results of the 
baseline assessment, provides feedback about their CVR profile and recommendations on 
how to improve it, and participants decide which CVRFs they want to act upon.  
3. Goal setting; the participants set “specific, measurable, attainable, realistic and time 
bound” (SMART) [38] goals to improve their lifestyle, with the guidance of the coach.    
4. Monitoring and support; the participants record and follow their progress towards a goal or 
related to the status of a specific CVRF, by entering specific measurements (e.g. blood 
pressure values) and updates on the platform, and receive feedback and support from both the 
platform and the coach.  
5. Evaluation of progress; the coach provides appropriate feedback based on what the 
participants record on the platform: further support, when improvements are not recorded, 
congratulations and recommendation on how to proceed, when goals are reached.  
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In order to define the eligibility for the intervention and the monitoring of each CVRF, 
adjustments were applied to this generic algorithm. Standardized criteria and cut-off values to 
identify participants eligible for both lifestyle and pharmacological intervention were defined 
(Table 4).  
In the guidelines, the CVR level affected the cut-off values for lifestyle and pharmacological 
interventions, but it was not consistently assessed in the three countries. Since HATICE 
inclusion criteria required for an age of 65+ and at least two CVRFs and/or history of CVD or 
DM, it could be assumed that the majority of the recruited participants had a high CVR, using 
any of the assessment methods. Therefore, the cut-off values for interventions were set for 
individuals with high CVR (Table 4).  
For DM, given that different tests or different cut-offs were used locally (Table 2), FPGT and 
HbA1C were selected because routinely available in each country. Three risk levels were 
then defined for both tests (Table 5). Participants with a blood glucose level beyond the 
“normal” range were recommended a lifestyle intervention, and were further advised to 
contact their general practitioner regarding potential pharmacological intervention if they had 
not discussed their blood glucose status with a doctor in the previous 6 months (Table 4). 
The cut-off value for lifestyle intervention of overweight/obesity was set at BMI ≥30. The 
guidelines reviewed, except the Finnish ones, called for a lifestyle intervention already in 
overweight people (25≤BMI<30), regardless of the age. However, an increasing body of 
evidence suggests that overweight older adults have an overall mortality risk equal or lower 
than those with normal BMI [39-43]. The increased risk of malnutrition in this age group is 
widely acknowledged [44-46], and it has been proposed that age-specific BMI cut-offs 
should be applied to more efficiently detect subjects at risk [47]. Since the broad ultimate 
scope of HATICE is to promote healthy ageing, people with a BMI in the overweight range 
were, therefore, only recommended to monitor their weight.  
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Nutrition guidelines were not as standardized as for other CVRFs. Cut-offs were provided 
mostly for single nutrients but not for foods, except fish, fruits, and vegetables, and overall 
assessment of the diet requires a complex evaluation of many components. The nutrition 
questionnaire from an international study for the early prevention of DM complications [48] 
was adapted, for HATICE, by the consortium’s expert nutritionists, through a consensus 
process. The questionnaire accounted for all dietary components linked to the CVR profile 
and included a validated dietary assessment tool [49]. Cut-offs for specific nutrient groups 
(fat, fibers, sugar, salt and alcohol), based on both their quality and quantity, were used to 
identify subjects who could benefit from changes in their diet.  
Physical activity was assessed at baseline through the Community Healthy Activities Model 
Program for Seniors (CHAMPS) questionnaire [50], a thorough validated tool to record 
weekly levels of physical as well as social and recreational activities. Throughout the 
intervention, a simplified exercise diary allowed participants to record any relevant activity. 
The recommendations provided throughout the intervention were based on the lifestyle 
components of the guidelines previously analyzed, and were delivered either via the platform 
or through the interaction with the coach. On the platform, recommendations were delivered 
through static and interactive education modules in form of text, videos, and pictures [28]. 
Information included: 1. background information on CVD, 2. recommendations for each 
individual CVRF, 3. practical tips aimed to translate recommendations in concrete actions 
that could fit in the person’s daily routine and individual lifestyle, 4. practical examples of 
“goals” to set during the intervention aimed to lifestyle improvement. To encourage 
participants to self-manage their risk factors, a tool to monitor personal data was included for 
each CVRF [28]. Participants were free to access the platform at their own convenience and 
decide their preferred frequency of use without any specific minimum or maximum 
requirement.  
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The coach provided the participants in the intervention arm with advice on their overall CVR 
and the relevant CVRFs, during both the baseline face-to-face meeting and the trial, and 
whenever in contact with the participants. Specific events triggered the coach feedback, 
including when participants set, edited, or updated the progress for a goal; recorded a 
measurement of a CVRF; or did not use the platform for more than three weeks. Overall, the 
role of the coach throughout the intervention was to offer motivational support, ensure that 
goals and expectations were realistic, encourage during the monitoring process, and promote 
long-term changes integrated in the overall lifestyle of each individual (Table 1). The 
motivational role of the coach was designed based on the “Stages of changes” model [30,31], 
which provides a framework to understand the mental processes involved in behavior change. 
The model is structured on five distinct stages: pre-contemplative; contemplative; 
preparation; action; and maintenance. Training on this theoretical model, and related 
motivational interviewing techniques, was provided to all the coaches prior to the trial. The 
workload in each country was shared among several coaches from diverse backgrounds. To 
optimize the consistency in the delivery of the intervention, a detailed coach protocol, which 
defined and standardized all the actions of the coach during the trial was prepared, regular 
meetings were organized among the coaches in each country, and once at an international 
level.  
Finally, the intervention delivered through the platform was supported by other interactive 
features including lifestyle groups (e.g., exercise groups), to promote peer support, and a 
computer-based cognitive training tool, adapted from a previous trial [51] and aimed  to 
improve cognitive domains more vulnerable to ageing (episodic memory, executive function, 
mental speed, and working memory). 
 Country-specific adaptations 
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The intervention was built on a number of key principles, which were kept constant to ensure 
a uniform approach in the participating countries: the intervention algorithm; the cut-off for 
eligibility; the functionality of the platform; and the overall components of the information 
and recommendations provided. However, once the generic intervention was designed, each 
country implemented minor changes to the coach protocol and platform informative content. 
Such adaptations accounted for country-specific cultural contexts, aimed to facilitate 
implementation and sustainability of the intervention and did not modify its substance or the 
way it was administered. Each country adapted their nutrition recommendations to suggest 
food items nutritionally equivalent to those mentioned in the generic intervention, but more 
consistent with local food habits and availability. Advice related to items deemed more 
relevant in specific countries, because of their high levels of consumption (e.g., liquorice in 
the Netherlands, and alcohol in Finland), were also added. Different examples of physical 
activities and exercise were suggested to account for geographical and climate differences. 
Other adjustments ensured that the intervention complemented with the existing healthcare. 
For example, Dutch primary care nurses have extensive experience in supporting smoking 
cessation. Therefore, as not to interfere with primary care policies, the Dutch coaches referred 
participants to primary care nurses for information on any type of medication aimed to 
support smoking cessation. Additionally, advice on non-supervised use of nicotine 
replacement therapy was removed from the Dutch platform. Finally, minor adaptations of the 
coach protocol and the platform were implemented to account for ethnic differences in 
countries with more heterogeneous populations.    
 
Discussion 
Current evidence suggests that CVRFs are not optimally controlled in a significant proportion 
of older adults [3,5,52], which offers opportunities for intervention. At the same time, 
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international experts and the WHO have called upon governments, world-wide, to make 
prevention of dementia one of their key health priorities [53-56]. Although the clear nature of 
the relationship between CVD and dementia is yet to be unraveled, the two conditions share 
several risk factors, therefore it is plausible to suppose that acting on lifestyle and CVRFs 
could help prevent not only CVD but also cognitive impairment [57-59]. Findings from 
recent RCTs [16-18] support beneficial effects of multidomain strategies, but robust evidence 
is lacking on how and to what extent older adults can benefit from lifestyle changes. The aim 
of the study was to develop a generic, evidence-based multidomain intervention administered 
through the internet, and supported by a coach, to improve the CVR profile of older adults. 
Although several medical-related risk factors were considered in the RCT, HATICE was not 
designed to compete with regular healthcare, but rather complement it; this was achieved by 
placing lifestyle management and improvement at the core of the intervention. The 
intervention had to be easily and consistently applicable in Northern, Central and Southern 
European settings. As a result, a balance was required between standardization of its design 
and compliance with national guidelines for CVRFs management, which were the backbone 
of the HATICE intervention, together with the ESC guidelines. National recommendations 
were used to define cut-off values for the included CVRFs as well as for the lifestyle advice 
provided throughout the intervention, while the ESC guidelines were the overarching 
reference when discrepancies among the national documents were identified. To ease and 
optimize the implementation of the intervention, minor country-specific modifications were 
also made to account for differences in culture, geography/climate as well as healthcare 
systems.  
Extensive similarities among the guidelines allowed the definition of a uniform intervention 
for most of the risk factors by directly integrating the national guidelines, with only few 
exceptions. For DM risk categories linked to specific cut-offs were created to facilitate the 
use of different country-specific routine tests. For diet, as no assessment tool standardized for 
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all the countries was identified, a short nutritional questionnaire, with validated elements to 
assess dietary components relevant for CVD prevention, was selected and adjusted to meet 
cross-cultural requirements. For BMI, the intervention accounted for recent scientific 
evidence of the role played by age. 
Overall, national and European guidelines lacked comprehensive and consistent 
recommendation for the management of CVRFs in older adults, which meant that the 
HATICE intervention strategy could not always be fully tailored to the target population. 
This reflects both the complexity of prevention in advanced age, where primary and 
secondary prevention can coexist, for example when considering individual risk factors as 
actual diseases, and the paucity of RCT-derived knowledge of optimal treatment thresholds 
and therapeutic targets in older adults. Significant differences existed among the guidelines 
analyzed in the assessment of the overall CVR. However, they did not impact the intervention 
design, as the recruited population was specifically selected to be at high risk of CVD. 
Differences were also apparent in the recommendations for pharmacological treatment, 
reflecting ongoing debates about optimal therapeutic targets for CVRFs for older adults. For 
instance, although the ESC guidelines for hypertension suggest higher BP values for 
individuals aged 80+, whether to control BP more or less strictly in older adults is still open 
to debate. Almost a decade ago, one of the few trials conducted still to date on very old adults 
(80+ years) [60] supported antihypertensive treatment for  SBP≥160mmHg, and therapeutic 
targets set at SBP<150mmHg and DBP<80mmHg. Recently, a trial aiming to compare 
intensive (<120mmHg) versus standard (<140mmHg) SBP targets reported that a more 
intensive BP control in individuals aged 75+ was beneficial for cardiovascular morbidity and 
mortality [61]. However, a significant proportion of its participants experienced orthostatic 
hypotension, which has been shown to increase the risk of dementia [62]. Similar issues exist 
for dyslipidemia [63,64]. Recommendations to initiate or modify pharmacological treatments 
were used in HATICE only to identify subjects who should be referred to primary healthcare, 
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therefore differences on pharmacological recommendations did not affect the design of the 
intervention. As change in medication use is recorded during the HATICE trial, the analysis 
of these data might contribute to better understand the role of pharmacotherapy in older 
adults.   
E-health solutions with interactive features could provide a simple, cost-effective, and widely 
accessible tool to increase awareness, educate, and promote self-management of CVRFs 
through improvement of lifestyle and adherence to pharmacological treatments, all relevant 
issues when planning public-health programs. The HATICE platform was successfully tested 
in a pilot study, and the full trial, which has included more than 2500 participants, is now 
ongoing [19]. If shown to be efficacious, it will be crucial to see if and to what extent such 
internet-based approaches can reach different populations, including assessment of the 
potential to increase inequalities. 
In conclusion, despite existing differences in the management of CVRFs, healthcare 
organization, and lifestyle habits within HATICE participating countries, a generic 
multidomain intervention could be designed and implemented uniformly. The design of the 
intervention was approached pragmatically, taking into account existing guidelines and recent 
scientific evidence from studies in older adults. A certain degree of flexibility was allowed in 
each country for the implementation of intervention, and minor adjustments were made 
locally to ensure adherence to the national guidelines. Given the constant evolution of the 
recommendations for the management of CVRFs, this adaptability could be of great help in 
future and larger applications. The HATICE trial can contribute to refine the knowledge on 
affordable strategies to manage CVRFs in older adults, and help to define Europe-wide 
applicable preventative programs for CVD and dementia.  
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Table 1: Summary of the key aspects of the HATICE trial design.  
BMI: body mass index; CAIDE: cardiovascular risk factors, aging, and incidence of dementia; CVD: 
Cardiovascular disease; CVRF: Cardiovascular risk factor; Fi: Finland; Fr: France; GP: general practitioner; 
Recruitment   
 Sources  GP practices (Nl, Fr), Population Registry (Fi), Prevention Center, Memory 
Clinics and Hospital consultations and Media advertisement (Fr) 
 Inclusion criteria Age = 65 years or more                                                                                                       
Available informant                                                                                                               
2 or more CVRFs (hypertension, dyslipidemia, overweight, active smoking, 
lack of physical exercise) [19]                                                                                                   
AND/OR                                                                                                                                 
History of CVD                                                                                                                  
Diabetes mellitus 
 Exclusion criteria Previously diagnosed dementia                                                                                           
MMSE score < 24                                                                                                                    
Any condition expected to limit the 18-months compliance and follow up                                                                                                                                                
Internet illiteracy defined as inability to send an email                                                                                         
Severe visual impairment interfering with operating a computer 
Visits and assessments   
 Baseline Full assessment (face-to-face visit, blood tests, online questionnaires) 
 3 monthly Adverse events (online questionnaire) 
 12 months Interim assessment (online questionnaires), adverse events and medication 
use (phone call) 
  18 months Full assessment (face-to-face visit, blood tests, online questionnaires) 
Outcomes  
 Primary Composite score based on the average z-score of the difference between 
baseline and 18 months follow-up of SBP, LDL and BMI 
 Secondary Difference between baseline and 18 months follow-up on the individual 
components of the primary outcome.                                                                                          
Difference in lifestyle related risk factors (PA, diet, smoking status)                                                                                                
Difference in estimated 10-year CVD risk based on the Framingham CVD 
risk score [65,66]                                                                                                                                               
Difference in the CAIDE [66]  score                                                                                                                                                        
Incident CVD, dementia and mortality                                                                                                             
Physical fitness                                                                                                                                            
Mood, disability, cognitive functioning                                                                                                        
Cost effectiveness 
Intervention components   
 Through the platform Information on CVD, CVRFs and their prevention                                                    
Goal setting                                                                                                                             
Monitoring of risk factors and goal progress                                                             
Feedback                                                                                                                                              
Peers interaction through lifestyle groups                                                                     
Alerts and reminders                                                                                                            
  Through the coach Assessment of eligibility                                                                                                    
Recommendations on CVRFs and their prevention                                                                                        
Initiation of the intervention                                                                                                     
Feedback and motivational support throughout the intervention                                                                                                        
Alerts and reminders                                                     
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LDL: low-density lipoproteins; MMSE: Mini mental state examination; Nl: The Netherlands; PA: physical 
activity; SBP: systolic blood pressure.    
 
Table 2: Summary of lifestyle-related recommendations in the Finnish, French and Dutch 
guidelines for the management of lifestyle-related cardiovascular risk factors (physical 
activity, smoking and diet) and minor differences.     
Fi: Finnish guidelines; Fr: French guidelines; Nl: Dutch guidelines. 
                                                                                                                                             
    
General Recommendations                         
(uniform in Fi, Fr and Nl)  
  Minor Differences 
Physical 
Activity 
  
At least 2.5 hours (moderate intensity) or 1.5 hours 
(vigorous intensity) of aerobic exercise/week 
  - 
Smoking 
 
- Immediate cessation                                                  
- Behavioral counselling to address psychological 
and physical addiction                                                          
- Nicotine replacement therapy and medications for 
nicotine withdrawal symptoms (Buproprion, 
Varenycline, Nortryptiline) considered under 
medical supervision 
 
- 
Diet   
Nutrient-based recommendations:                                
- reduced intake of saturated and trans fats                   
- increased intake of mono- and poly-unsaturated fats                                                                             
- reduced intake of salt                                                 
- reduced intake of refined sugar                                   
- increased intake of dietary fiber                                                                                                     
Translated into food-level recommendations:                  
- at least 5 portions/day of fruits and vegetables                 
- regular consumption of wholegrain cereal products   
- consumption of low-fat dairy and meat products        
- limitation of sucrose intake                                           
- use of vegetable oil and margarine instead of butter 
- at least 2 portions/week of fish  
Recommended maximum alcohol intake/day:                                                      
- 1 (women) and 2 (men) units (Fi and Nl)                                                        
- 2 (women) and 3 (men) units (Fr) 
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Table 3. Cut-off values to initiate lifestyle interventions or pharmacological treatments for four cardiovascular risk factors, based on the 
guidelines for the management of CVD published in Finland, France, the Netherlands, and by the ESC. For blood pressure, the cut-off values 
used for people at high risk of CVD are shown. 
  Blood Pressure (mmHg) Cholesterol (mmol/L) Blood Glucose (mmol/L) Weight (kg/m2) 
  
Lifestyle 
Intervention 
Pharmacological 
Intervention 
Lifestyle 
Intervention 
Pharmacological 
Intervention 
Lifestyle 
Intervention 
Pharmacological 
Intervention 
Lifestyle 
Intervention 
Pharmacological 
Intervention/Surgery 
Finland 
SBP≥130               
DBP≥85  
SBP≥160 
DBP≥100  
FINRISK*>10%  
OR LDL ≥ 2.5 
FINRISK* > 10% 
and LDL > 2.5 
or 
FINRISK*> 15% 
and LDL ≥ 1.8 
FPGT>6   
OGTT>7.8          
or 
Increased risk** 
FPGT≥7      
OGTT≥11       
HbA1C≥6.5% 
BMI ≥ 25 
Consider if BMI≥30 
Specialist consultation 
if BMI >35 and 
comorbidities or  
BMI > 40  
France 
SBP≥140                  
DBP≥90   
If BP is not in 
target after 3 
months of LI 
LDL>1.6 
If LDL is not in 
target after 3 
months of LI 
FPGT>7       
OGTT>11                
HbA1C≥6.0% 
HbA1C≥6.0% after  
3 months of LI 
BMI ≥ 25 
Consider if BMI≥40 
or ≥35  and 
comorbidities 
The 
Netherlands 
Presence of 1 or 
more modifiable 
risk factors 
SBP≥140 and 
increased risk*** 
or            
SBP≥180  
Presence of 1 or 
more modifiable 
risk factors 
LDL>2.5  
FPGT≥7          
RPG>11                 
HbA1C≥6.5% 
FPGT≥7          
RPG>11    
HbA1C≥6.5% 
BMI ≥ 25 NA 
ESC/EACPR 
SBP≥130                         
DBP≥85 
SBP≥160                     
DBP≥100  
Anybody  LDL>2.5 HbA1C≥7.0% HbA1C≥7.0% BMI ≥ 25 
 BMI≥40                     
or ≥35  and 
comorbidities 
BMI: body mass index; BP: blood pressure; DBP: diastolic blood pressure; EACPR: European association of cardiology prevention and rehabilitation; ESC: European 
society of cardiology; FINRISK: FINRISK risk calculator score that predicts 10-year risk for coronary heart disease and stroke incidence based on the national FINRISK 
study;[36] FPGT: fasting plasma glucose test; HbA1C: hemoglobin A1C; LDL: low density lipoproteins; LI: lifestyle intervention; OGTT: oral glucose tolerance test; RPG: 
random plasma glucose; SBP: systolic blood pressure.  
* ESC SCORE [27] (Systematic coronary risk evaluation) can also be used to assess overall cardiovascular risk. 
**Assessed with FINDRISC [67] score.  
***Defined as: 1. 10-year risk of morbidity and mortality from CVD ≥ 20% and/or LDL> 2.5 mmol/l, or 2. 10-year risk of morbidity and mortality from CVD = 10-20% 
and/or LDL> 2.5 mmol/L and presence of other risk-increasing factors. 
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Table 4. Cut-off values that determine, for each cardiovascular risk factor, the 
recommendation to either initiate a lifestyle intervention or seek medical advice for the 
HATICE participants within the intervention arm.  
Risk Factor Cut-off for lifestyle intervention Cut-off for contacting primary care doctor 
Blood pressure SBP > 140 mmHg  
DBP > 90 mmHg 
SBP > 140 mmHg, DBP > 90 mmHg 
OR 
SBP > 160 mmHg, DBP > 100 mmHg 
(if age ≥ 80) 
Dyslipidemia All participants  LDL ≥ 2.5 mmol/L OR                                              
all participants with history of CVD 
Diabetes Mellitus Blood glucose in the “at risk” or 
“abnormal” range* 
OR previous diagnosis of DM 
Blood glucose in the “at risk” or 
“abnormal” range* 
Previous diagnosis of DM AND               
no regular medical checks  
Overweight BMI ≥ 30 kg/m2 BMI ≥ 35 kg/m2 
Diet Overall questionnaire score ≤ 32/38 OR  
score in a specific food area**< 50%  
- 
Physical activity Weekly aerobic activity < 2.5 hours - 
Smoking Current smoker Cigarettes smoked daily ≥ 10  
BMI: Body Mass Index; CVD: cardiovascular disease; DBP: Diastolic Blood Pressure; DM: Diabetes Mellitus; 
LDL: low-density lipoproteins; SBP: Systolic Blood Pressure.  
* The values of blood glucose assessed with different tests and the related ranges are presented in Table 5. 
** Nutrition score included qualitative and quantitative information in five diet components: fat, fibers, salt, 
sugar, and alcohol. Higher results in nutrition score indicate better diet quality. 
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Table 5: Risk levels of diabetes mellitus based on ranges of blood glucose values assessed 
using different tests. 
Range 
Test Type 
FPGT (mmol) HbA1C (%) 
Normal x ≤ 6.0 x ≤ 6.0 
Risk 6.0 < X < 7.0 6.0 < X < 7.0 
Abnormal x ≥ 7.0 x ≥ 7.0 
FPGT: fasting glucose plasma test; HbA1C: hemoglobin A1C. 
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Figure legend 
Figure 1. Generic algorithm of the multidomain intervention applied to all the risk factors 
considered. CVRF=Cardiovascular risk factor, LI=Lifestyle intervention, 
PI=Pharmacological intervention, GP=General practitioner. 
 
 
